ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key marketed products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and ophthalmic viscoelastic products (e.g., AMVISC, CoEase). The company relies heavily on strategic partnerships for distribution and development, including agreements with Ortho Biotech (Johnson & Johnson) for ORTHOVISC and Bausch & Lomb for ophthalmic products.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 72% year-over-year, driven by a 45% increase in product revenue and a significant surge in licensing/milestone revenue.
• Product Mix Shift: ORTHOVISC sales grew 183% to $8.70 million following its U.S. launch in March 2004. Ophthalmic products grew 10% to $11.53 million. HYVISC grew 18% to $2.05 million.
• Licensing Milestones: The company received $27.0 million in upfront and milestone payments from Ortho Biotech (Johnson & Johnson) related to the ORTHOVISC agreement. These are recognized ratably over 10 years, contributing $4.18 million to 2004 revenue.
• Profitability: Net income surged from $0.83 million to $11.19 million. This was significantly aided by a one-time non-cash income tax benefit of $7.04 million resulting from the release of a valuation allowance against deferred tax assets.
• Operating Expenses: R&D expenses increased 57% to $4.09 million due to clinical trials for cosmetic tissue augmentation (CTA) and INCERT. SG&A expenses increased 44% to $6.04 million, largely due to Sarbanes-Oxley compliance costs.

Guidance, Outlook, and Risks

• Outlook: Management expects 2005 ORTHOVISC unit sales to the U.S. distributor to be below 2004 levels due to inventory buildup, though royalties from end-user sales are expected to increase. Ophthalmic sales are expected to decrease in 2005 as the agreement with Advanced Medical Optics expires in July 2005.
• Reimbursement Risks: ORTHOVISC sales growth in the U.S. was slower than anticipated due to the lack of a unique reimbursement code for physician offices (J-code). While a unique code for hospitals (C-code) was assigned effective January 2005, the lack of a J-code may continue to impact physician adoption.
• Development Pipeline: The company is conducting pivotal clinical trials for a cosmetic tissue augmentation (CTA) product and a pilot trial for INCERT-S (adhesion prevention). Success depends on FDA approval and commercialization by partners (OrthoNeutrogena).
• Customer Concentration: Three customers accounted for 73% of product revenue in 2004. The loss of major partners like Bausch & Lomb or Ortho Biotech would materially harm the business.
• Regulatory Risks: Future products (CTA, INCERT) require Class III medical device approval (PMA), which is costly and time-consuming. Failure to obtain approval would halt commercialization.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the ratable recognition schedule of the $27.0 million Ortho Biotech milestone payments over the 10-year term.
• Reimbursement Status: Monitor the status of the unique J-code application for ORTHOVISC in physician offices, as this is critical for U.S. sales volume.
• Customer Concentration: Assess the risk associated with the expiration of the Advanced Medical Optics agreement in July 2005 and the reliance on Bausch & Lomb (38% of product revenue).
• Cash Burn vs. Milestones: Confirm that the strong cash position ($39.3 million) is sufficient to fund R&D and operations until future milestone payments or product revenues materialize.
• One-Time Tax Benefit: Distinguish between the $7.04 million non-cash tax benefit and the $6.39 million operating income when evaluating core operational profitability.